openPR Logo
Press release

Glaucoma Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Q BioMed, InMed Pharmaceuticals, ONL Therapeutics, Mitotech, TheratOcular Biotek

05-03-2024 09:02 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Glaucoma Pipeline and Clinical Trials Assessment, 2024

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Glaucoma pipeline constitutes 50+ key companies continuously working towards developing 50+ Glaucoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Glaucoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glaucoma Market.

The Glaucoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Glaucoma Pipeline Report: https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Glaucoma treatment therapies with a considerable amount of success over the years.
• Glaucoma companies working in the treatment market are Q BioMed, InMed Pharmaceuticals, ONL Therapeutics, Mitotech, TheratOcular Biotek Co., Ltd., AbbVie, JeniVision, Qlaris Bio, VivaVivion Biotech, Inc., Nicox, Tarsier Pharma Ltd, Santen Pharmaceutical, and others, are developing therapies for the Glaucoma treatment
• Emerging Glaucoma therapies in the different phases of clinical trials are- MAN-01, INM-088, ONL 1204, Visomitin, TO-O-1001, AGN-193408, JV-GL1, QLS-101, VVN539, NCX 470, TRS01, STN-1012600, and others are expected to have a significant impact on the Glaucoma market in the coming years.
• In November 2023, Using its patented ELUTYXTM bioresorbable hydrogel-based formulation technology, Ocular Therapeutix, Inc. is a biopharmaceutical business dedicated to the formulation, development, and commercialization of cutting-edge medicines for illnesses and disorders of the eye.
• In December 2022, Visiox Pharma disclosed that it received confirmation from the US Food and Drug Administration (FDA) indicating the completion of its review of the filing and acceptance of the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) intended for treating glaucoma.
• In October 2022, Essex Biotechnology Ltd revealed that its fully-owned subsidiary, Essex Bioinvestment Ltd, has finalized (i) a patent and know-how license agreement; and (ii) a patent assignment deed concerning SkQ1, an active pharmaceutical ingredient from Mitotech S.A. These agreements grant Essex Bioinvestment global rights (excluding Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia) and interests in SkQ1, exclusively for use in the field of ophthalmology, and are transferable and irrevocable.

Glaucoma Overview
Glaucoma is a group of eye conditions that damage the optic nerve, which is crucial for good vision. It's often associated with high pressure inside the eye, known as intraocular pressure. Glaucoma can lead to gradual vision loss and, if untreated, eventual blindness.


Get a Free Sample PDF Report to know more about Glaucoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Glaucoma Drugs Under Different Phases of Clinical Development Include:
• MAN-01: Q BioMed
• INM-088: InMed Pharmaceuticals
• ONL 1204: ONL Therapeutics
• Visomitin: Mitotech
• TO-O-1001: TheratOcular Biotek Co., Ltd.
• AGN-193408: AbbVie
• JV-GL1: JeniVision
• QLS-101: Qlaris Bio
• VVN539: VivaVivion Biotech, Inc.
• NCX 470: Nicox
• TRS01: Tarsier Pharma Ltd
• STN-1012600: Santen Pharmaceutical

Glaucoma Route of Administration
Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Glaucoma Molecule Type
Glaucoma Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide

Glaucoma Pipeline Therapeutics Assessment
• Glaucoma Assessment by Product Type
• Glaucoma By Stage and Product Type
• Glaucoma Assessment by Route of Administration
• Glaucoma By Stage and Route of Administration
• Glaucoma Assessment by Molecule Type
• Glaucoma by Stage and Molecule Type

DelveInsight's Glaucoma Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Glaucoma product details are provided in the report. Download the Glaucoma pipeline report to learn more about the emerging Glaucoma therapies at:
https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Glaucoma Therapeutics Market include:
Key companies developing therapies for Glaucoma are - Aerie Pharmaceuticals Inc., Akorn, Incorporated, Abbvie Inc. (Allergan Plc), Bausch Health (Bausch & Lomb Incorporated), Inotek Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc, Santen Pharmaceutical Co., Ltd., and others.

Glaucoma Pipeline Analysis:
The Glaucoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Glaucoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glaucoma Treatment.
• Glaucoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glaucoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glaucoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glaucoma drugs and therapies-
https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glaucoma Pipeline Market Drivers
• Growing Prevalence of glaucoma, development of novel therapies, growing awareness due to government initiatives and pharmaceutical companies are some of the important factors that are fueling the Glaucoma Market.

Glaucoma Pipeline Market Barriers
• However, high medical cost, side-effects associated with the drugs and other factors are creating obstacles in the Glaucoma Market growth.

Scope of Glaucoma Pipeline Drug Insight
• Coverage: Global
• Key Glaucoma Companies: Q BioMed, InMed Pharmaceuticals, ONL Therapeutics, Mitotech, TheratOcular Biotek Co., Ltd., AbbVie, JeniVision, Qlaris Bio, VivaVivion Biotech, Inc., Nicox, Tarsier Pharma Ltd, Santen Pharmaceutical, and others
• Key Glaucoma Therapies: MAN-01, INM-088, ONL 1204, Visomitin, TO-O-1001, AGN-193408, JV-GL1, QLS-101, VVN539, NCX 470, TRS01, STN-1012600, and others
• Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
• Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers

Request for Sample PDF Report for Glaucoma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Glaucoma Report Introduction
2. Glaucoma Executive Summary
3. Glaucoma Overview
4. Glaucoma- Analytical Perspective In-depth Commercial Assessment
5. Glaucoma Pipeline Therapeutics
6. Glaucoma Late Stage Products (Phase II/III)
7. Glaucoma Mid Stage Products (Phase II)
8. Glaucoma Early Stage Products (Phase I)
9. Glaucoma Preclinical Stage Products
10. Glaucoma Therapeutics Assessment
11. Glaucoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Glaucoma Key Companies
14. Glaucoma Key Products
15. Glaucoma Unmet Needs
16 . Glaucoma Market Drivers and Barriers
17. Glaucoma Future Perspectives and Conclusion
18. Glaucoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Glaucoma Market https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Glaucoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Glaucoma Epidemiology https://www.delveinsight.com/report-store/glaucoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Glaucoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glaucoma Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Q BioMed, InMed Pharmaceuticals, ONL Therapeutics, Mitotech, TheratOcular Biotek here

News-ID: 3484446 • Views:

More Releases from DelveInsight Business Research

Urinary Retention Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, Companies by DelveInsight
Urinary Retention Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trial …
(Albany, USA) DelveInsight's "Urinary Retention Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Urinary Retention, historical and forecasted epidemiology as well as the Urinary Retention market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Urinary Retention market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Urinary Retention
Oral Mucositis Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Oral Mucositis Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials …
(Albany, United States) As per DelveInsight's assessment, globally, the Oral Mucositis Pipeline constitutes 10+ Oral Mucositis companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. "Oral Mucositis Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Oral Mucositis Therapeutics Market. The report provides
Nosocomial Pneumonia Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Nosocomial Pneumonia Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical …
(Albany, USA) DelveInsight's, "Nosocomial Pneumonia Pipeline Insight, 2024" report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in the Nosocomial Pneumonia pipeline landscape. It covers the Nosocomial Pneumonia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nosocomial Pneumonia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from
Intracerebral Hemorrhage Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, Companies by DelveInsight | ClearMind Biomedical, Medtronic, Stryker, InfraScan, MicroPort Scientific Corporation, Penumbra, Inc., Acandis G
Intracerebral Hemorrhage Market Forecast 2032: FDA, EMA, PDMA Approvals, Clinica …
(Albany, USA) DelveInsight's "Intracerebral Hemorrhage Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Intracerebral Hemorrhage, historical and forecasted epidemiology as well as the Intracerebral Hemorrhage market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Intracerebral Hemorrhage market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Intracerebral Hemorrhage market

All 5 Releases


More Releases for Glaucoma

Micro-Invasive Glaucoma Implants Micro-Invasive Glaucoma Implants
Global Micro-Invasive Glaucoma Implants Market Definition: Micro-invasive glaucoma implants is performed for the treatment of the open- angle glaucoma and is done through an ab- interno approach. It is very safe and provides faster recovery as compared to the traditional methods. They usually lower the intraocular by increasing the flow or reducing the production of the aqueous humor. Increasing cases of the glaucoma worldwide is the major factor fueling the
Glaucoma – Epidemiology Insights (2016-2028)
Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1159 The common identifiable features for all forms of glaucoma are loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and cupping of the
Market Spotlight: Glaucoma
Boston, MA ReportsWorldwide has announced the addition of a new report title Market Spotlight: Glaucoma to its growing collection of premium market research reports. Glaucoma is not just one eye disease, but a group of eye conditions resulting in optic nerve damage, which may cause loss of vision and blindness. In glaucoma, damage to the optic nerve is usually caused by elevated intraocular pressure (IOP). IOP rises when passages that allow fluid
North America Glaucoma Therapeutics Market grows with growing awareness regardin …
Glaucoma Therapeutics Market: Scope and Methodology The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study
Glaucoma Treatment Market : Rising Geriatric Population And Healthcare Expenditu …
Glaucoma is a chronic, degenerative, permanent disorder whose rate increases essentially with age rather than causing immediate blindness. According to a survey of WHO, Glaucoma is the second most common cause of blindness affecting the population worldwide after cataract (47.9%). In general, Glaucoma occurs as after effects of increased intraocular pressure (IOP) brought about by an abnormality or malfunctioning of the eye drainage system. The normal IOP is in
Glaucoma Surgery Devices Market 2016: Glaucoma Systems, Glaucoma Laser Devices
Latest industry research report on Glaucoma surgery devices are used in the glaucoma treating procedure. These procedures include both surgical and laser therapies performed on a patient. The cases of blindness due to glaucoma is on rise across the several countries. Furthermore, the demand for both technologically as well as advanced surgical equipment has resulted in the popularity of glaucoma surgery devices industry, worldwide. Sudden increase in the aging population and